A bipartisan US Senate bill reintroduced the “Pharmaceutical Investment Oversight and Accountability Act,” aiming to increase transparency around foreign influence across the US drug supply chain. The draft legislation would require mapping of foreign manufacturing presence and assess how foreign investment affects domestic production. While the bill does not name specific countries, co-sponsor Sen. Rick Scott highlighted China in testimony and argued that the US depends heavily on foreign sources of key starting materials and APIs. Proposed reporting roles would involve the FTC and the Department of the Treasury, alongside ongoing federal mechanisms like CFIUS. The policy direction matters for companies with cross-border manufacturing footprints because it expands scrutiny beyond physical supply to ownership structures—potentially altering risk assessments for partnerships and capital allocation.